Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting

PharmacoEconomics

Volumn 11, Issue 6, 1997, Pages 595-605

  Pelc, Alain ^a,e   Dardenne, Jacques ^b   Frelon, Jean Hughes ^c   Hanania, Guy ^d  

^a Health Economics Department   (France)

^b IMS France   (France)

^c BOEHRINGER INGELHEIM   (France)

^d Centre Hospitalier Robert Ballanger CHRB   (France)

^e IMS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ACUTE HEART INFARCTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FRANCE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030738385     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711060-00007     Document Type: Article

References (19)

1. AIMS Trials Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; I: 545-9
2. Wilcox RG, von der Lippe G, Ollson CF, ASSET Study Group, et al. Trial of tissue plasminogen activation for mortality reduction in acute myocardial infarction. Lancet 1988; II: 525-30
3. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI-I). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397-402
4. ISAM Study Group. A prospective placebo-controlled double-blind multicentre trial of intravenous streptokinase in acute myocardial infarction - long term mortality and morbidity. J Am Coll Cardiol 1987; 9: 127-203
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase and oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349-60
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
7. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
8. Arvieler D, Hedelin G, Nuttens MC, et al. Evaluation et comparaison de la prise en charge médicale des patients recensés dans les trois registres français des cardiopathies ischémiques. Recherche et Politiques de Santé Paris: Edition INSERM, 1992: 109-14
9. Nuttens MC, Salomez JL, Cambou JP, et al. L'infarctus du myocarde dans trois régions françaises: comparaison de l'incidence et de la mortalité, 1985-1988. Recherche et Politiques de Santé. Paris: Edition INSERM, 1992: 11-6
10. Douste-Blazy P, Ruidavets JB, Arvieler D, et al. Facteurs de risque cardio-vasculaire dans lu population de deux régions couvertes par les registres MONICA-FRANCE: Strasbourg et Toulouse. Rev Epidemiol Sante Publique 1988; 36: 342-9
11. Monassier JP, Hanania G, Khalifé K, et al. Stratégies théreapeutiques à la phase aiguë de l'infarctus du myocarde: résultats du registre STIM 93. Arch Mal Coeur Vaiss 1996; 89: 281-9
12. Machecourt J, Foroni L, Dumoulin J, et al. Aspect économique de la thrombolyse à la phase aigüe de l'infarctus du myocarde. Le choix du thrombolytique. JAMA (Edition Hospitalière Française) Sep 1993 Suppl.: 41-8
13. Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. JAMA 1995; 273: 1586-91
14. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850-5
15. Freemantle N, Drummond M. Should clinical trials with concurrent economic analyses be blinded? JAMA 1997; 277: 63-4
16. Goldman I, Weinstein MC, Goldman PA. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51
17. Le Pen C, Levy E, Bonte J. L'analyse coût-efficacité du traitement par captopril après infarctus du myocarde. Arch Mal Coeur 1994; 87: 775-81
18. Smith JT, Hillner BE, Desch CF. Efficacy and cost-effectiveness of cancer treatment, rational allocation based on decision analysis. J Natl Cancer Ins 1993; 85: 1460-74
19. Loisance D, Benvenuti C, Lebrun T, et al. Coût-efficacité des stratégies thérapeutiques chez les candidats à la transplantation cardiaque de sauvetage. Evaluation des innovations technologiques et décisions en Santé Publique. Paris: Edition INSERM, 1992: 147-58